BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33855952)

  • 21. MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease.
    Panera N; Gnani D; Crudele A; Ceccarelli S; Nobili V; Alisi A
    World J Gastroenterol; 2014 Nov; 20(41):15079-86. PubMed ID: 25386056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease.
    Fernández-Tussy P; Fernández-Ramos D; Lopitz-Otsoa F; Simón J; Barbier-Torres L; Gomez-Santos B; Nuñez-Garcia M; Azkargorta M; Gutiérrez-de Juan V; Serrano-Macia M; Rodríguez-Agudo R; Iruzubieta P; Anguita J; Castro RE; Champagne D; Rincón M; Elortza F; Arslanow A; Krawczyk M; Lammert F; Kirchmeyer M; Behrmann I; Crespo J; Lu SC; Mato JM; Varela-Rey M; Aspichueta P; Delgado TC; Martínez-Chantar ML
    Mol Metab; 2019 Nov; 29():40-54. PubMed ID: 31668391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Series of microRNA in the Chromosome 14q32.2 Maternally Imprinted Region Related to Progression of Non-Alcoholic Fatty Liver Disease in a Mouse Model.
    Okamoto K; Koda M; Okamoto T; Onoyama T; Miyoshi K; Kishina M; Kato J; Tokunaga S; Sugihara TA; Hara Y; Hino K; Murawaki Y
    PLoS One; 2016; 11(5):e0154676. PubMed ID: 27135827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BMP4 and Gremlin 1 regulate hepatic cell senescence during clinical progression of NAFLD/NASH.
    Baboota RK; Rawshani A; Bonnet L; Li X; Yang H; Mardinoglu A; Tchkonia T; Kirkland JL; Hoffmann A; Dietrich A; Boucher J; Blüher M; Smith U
    Nat Metab; 2022 Aug; 4(8):1007-1021. PubMed ID: 35995996
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential epigenetic mechanism in non-alcoholic Fatty liver disease.
    Sun C; Fan JG; Qiao L
    Int J Mol Sci; 2015 Mar; 16(3):5161-79. PubMed ID: 25751727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miRNA Regulation of Glucose and Lipid Metabolism in Relation to Diabetes and Non-alcoholic Fatty Liver Disease.
    Suksangrat T; Phannasil P; Jitrapakdee S
    Adv Exp Med Biol; 2019; 1134():129-148. PubMed ID: 30919335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetics in non-alcoholic fatty liver disease.
    Lee J; Kim Y; Friso S; Choi SW
    Mol Aspects Med; 2017 Apr; 54():78-88. PubMed ID: 27889327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease.
    Baranova A; Schlauch K; Elariny H; Jarrar M; Bennett C; Nugent C; Gowder SJ; Younoszai Z; Collantes R; Chandhoke V; Younossi ZM
    Obes Surg; 2007 Aug; 17(8):1111-8. PubMed ID: 17953248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sex- and age-specific associations between abdominal fat and non-alcoholic fatty liver disease: a prospective cohort study.
    Chen H; Liu Y; Liu D; Liang Y; Zhu Z; Dong K; Li H; Bao Y; Wu J; Hou X; Jia W
    J Mol Cell Biol; 2024 Apr; 15(11):. PubMed ID: 38037475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A retrospective case control study identifies peripheral blood mononuclear cell albumin RNA expression as a biomarker for non-alcoholic fatty liver disease.
    Chu X; Karasinski K; Donellan S; Kaniper S; Wood GC; Shi W; Edwards MA; Soans R; Still CD; Gerhard GS
    Langenbecks Arch Surg; 2020 Mar; 405(2):165-172. PubMed ID: 31828503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deregulated hepatic microRNAs underlie the association between non-alcoholic fatty liver disease and coronary artery disease.
    Braza-Boïls A; Marí-Alexandre J; Molina P; Arnau MA; Barceló-Molina M; Domingo D; Girbes J; Giner J; Martínez-Dolz L; Zorio E
    Liver Int; 2016 Aug; 36(8):1221-9. PubMed ID: 26901384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced A-FABP expression in visceral fat: potential contributor to the progression of NASH.
    Yoon MY; Sung JM; Song CS; Lee WY; Rhee EJ; Shin JH; Yoo CH; Chae SW; Kim JY; Jin W; Cho YK
    Clin Mol Hepatol; 2012 Sep; 18(3):279-86. PubMed ID: 23091808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Emerging Role of MicroRNAs in NAFLD: Highlight of MicroRNA-29a in Modulating Oxidative Stress, Inflammation, and Beyond.
    Lin HY; Yang YL; Wang PW; Wang FS; Huang YH
    Cells; 2020 Apr; 9(4):. PubMed ID: 32331364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The inhibitory effect of genistein on hepatic steatosis is linked to visceral adipocyte metabolism in mice with diet-induced non-alcoholic fatty liver disease.
    Kim MH; Kang KS; Lee YS
    Br J Nutr; 2010 Nov; 104(9):1333-42. PubMed ID: 20687969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fructo-oligosaccharides ameliorate steatohepatitis, visceral adiposity, and associated chronic inflammation via increased production of short-chain fatty acids in a mouse model of non-alcoholic steatohepatitis.
    Takai A; Kikuchi K; Ichimura M; Tsuneyama K; Moritoki Y; Matsumoto K; Tsunashima H; Onda T; Kuniyoshi N; Nariyama T; Ohyatsu S; Kubota J; Nagumo K; Sato S; Hara M; Miyakawa H
    BMC Gastroenterol; 2020 Feb; 20(1):46. PubMed ID: 32103741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of MicroRNAs in Pathophysiology of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis.
    Iravani F; Hosseini N; Mojarrad M
    Middle East J Dig Dis; 2018 Oct; 10(4):213-219. PubMed ID: 31049168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum vitamin D levels are inversely related with non-alcoholic fatty liver disease independent of visceral obesity in Chinese postmenopausal women.
    Lu Z; Pan X; Hu Y; Hao Y; Luo Y; Hu X; Ma X; Bao Y; Jia W
    Clin Exp Pharmacol Physiol; 2015 Feb; 42(2):139-45. PubMed ID: 25363574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Non-alcoholic fatty liver disease (NAFLD) /non-alcoholic steatohepatitis (NASH) and nutrition].
    Ishii KA; Takamura T
    Clin Calcium; 2016 Mar; 26(3):363-7. PubMed ID: 26923972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
    Pierantonelli I; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.